Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy.
Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy.
复制标题
DOI：
10.1016/j.cca.2021.09.022
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Lippi G
中科院分区：
文献类型：
--
作者：
Raposo F;Lippi G
测定抗sars - cov -2 RBD igg抗体反应对确定COVID-19疫苗接种者免疫动态非常重要。分析了4例错误接种过量疫苗的BNT162b2疫苗接种者在不同时间点的血清。在第6天，三名SARS-CoV-2 naïve受体的血清抗体增加相似。在第14天，抗体水平增加并达到峰值，尽管在三个接受者中显示出不同的模式。21 d时血清抗体水平开始从最高值下降。先前感染受体的数据与COVID-19阳性受体的数据一致。因此，初始剂量的疫苗足以引起显著的抗体反应。尽管过量，但本研究证实了BNT162b疫苗在牛津/阿斯利康之前接种过疫苗的受者中作为异源增强疫苗以及在COVID-19感染的受者中作为原疫苗引发持续抗体反应的效率。重要的是，接受者的体液免疫反应与疫苗过量不成比例。尽管如此，我们不能描述疫苗过量对抗sars - cov -2抗体反应的单一影响，因为所发现的值是高度异质性的。
Measurement of anti-SARS-CoV-2 RBD Ig G antibody response is very important to define the dynamics of immunization in vaccine COVID-19 recipients. Sera from four BNT162b2 vaccine recipients who erroneously received vaccine overdose were analyzed at different time-points. At 6 days the serum increase of antibodies was analogous for the three SARS-CoV-2 naïve recipients. At 14 days the antibody level increased and reached a peak, though showing a different pattern among the three recipients. At 21 days the serum antibody level started to decrease from its maximum value. The data for the previously infected recipient were in agreement with values found in COVID-19 positive receivers. Thus, the prime-dose of vaccine was enough to elicit a significant antibody response. In spite of the overdosage, this study confirms the efficiency of the BNT162b vaccine in eliciting a sustained antibody response as heterologous boost-vaccine in previously Oxford/AstraZeneca vaccinated recipients, as well as, prime-vaccine in COVID-19 infected receivers. Importantly, the humoral immune response of recipients was not proportional to the vaccine overdose. Nonetheless, we cannot portray a univocal effect of vaccine overdose concerning anti-SARS-CoV-2 antibody response because the values found were highly heterogeneous.
登录
查看更多内容
DOI：
10.3390/diagnostics11060941
发表时间：
2021-05-25
期刊：
Diagnostics (Basel, Switzerland)
影响因子：
--
作者：
Lippi G;Henry BM;Plebani M
通讯作者：
Plebani M
DOI：
10.1084/jem.20201707
发表时间：
2021-03-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Rodrigues TS;de Sá KSG;Ishimoto AY;Becerra A;Oliveira S;Almeida L;Gonçalves AV;Perucello DB;Andrade WA;Castro R;Veras FP;Toller-Kawahisa JE;Nascimento DC;de Lima MHF;Silva CMS;Caetite DB;Martins RB;Castro IA;Pontelli MC;de Barros FC;do Amaral NB;Giannini MC;Bonjorno LP;Lopes MIF;Santana RC;Vilar FC;Auxiliadora-Martins M;Luppino-Assad R;de Almeida SCL;de Oliveira FR;Batah SS;Siyuan L;Benatti MN;Cunha TM;Alves-Filho JC;Cunha FQ;Cunha LD;Frantz FG;Kohlsdorf T;Fabro AT;Arruda E;de Oliveira RDR;Louzada-Junior P;Zamboni DS
通讯作者：
Zamboni DS
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
DOI：
10.1016/s0140-6736(21)01420-3
发表时间：
2021-07-10
期刊：
Lancet (London, England)
影响因子：
--
作者：
Borobia AM;Carcas AJ;Pérez-Olmeda M;Castaño L;Bertran MJ;García-Pérez J;Campins M;Portolés A;González-Pérez M;García Morales MT;Arana-Arri E;Aldea M;Díez-Fuertes F;Fuentes I;Ascaso A;Lora D;Imaz-Ayo N;Barón-Mira LE;Agustí A;Pérez-Ingidua C;Gómez de la Cámara A;Arribas JR;Ochando J;Alcamí J;Belda-Iniesta C;Frías J;CombiVacS Study Group
通讯作者：
CombiVacS Study Group
先前感染状态，定量SARS-COV-2抗尖峰反应对辉瑞-biontech和牛津 - 震中疫苗的反应。
DOI：
10.1016/j.cmi.2021.05.041
发表时间：
2021-10
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Eyre DW;Lumley SF;Wei J;Cox S;James T;Justice A;Jesuthasan G;O'Donnell D;Howarth A;Hatch SB;Marsden BD;Jones EY;Stuart DI;Ebner D;Hoosdally S;Crook DW;Peto TEA;Walker TM;Stoesser NE;Matthews PC;Pouwels KB;Walker AS;Jeffery K
通讯作者：
Jeffery K